Table 1.

Cost effectiveness model overview

Aspect	Details
Analytical method	Markov state transition model incorporating a decision tree
Software used	Microsoft Excel 2010
Model perspective	UK NHS
Time horizon	1 year
Cycle length	4 weeks
Patient population	Men with LUTS/BPH who have moderate-to-severe storage symptoms (≥8 micturitions/day and ≥2 urgency episodes/day*) and voiding symptoms
Treatments	Once-daily FDC tablet of solifenacin 6 mg plus TOCAS 0.4 mg
	Tolterodine ER 4 mg plus tamsulosin 0.4 mg daily, given concomitantly
Outcomes	Total treatment costs
	Quality adjusted life years
	Incremental cost-effectiveness ratio

*Patient Perception of Intensity of Urgency Scale, grade 3 or 4.

BPH, benign prostatic hyperplasia; ER, extended release; FDC, fixed-dose combination; LUTS, lower urinary tract symptoms; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.